41326 Results for: "2-Amino-5,6-dimethylbenzothiazole"

Supplier: Abgent

Polyclonal antibody, Isotype: Rabbit Ig, Species reactivity: Human, Gene ID: 5463, Target/Specificity: This POU6F1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 56-85 amino acids from the N-terminal region of human POU6F1.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: MilliporeSigma

Cas Number 56-45-1, For Synthesis

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: TCI America

CAS Number: 32986-56-4
MDL Number: MFCD00077885
Molecular Formula: C18H37N5O9
Molecular Weight: 467.52
Purity/Analysis Method: >94.0% (T)
Form: Crystal
Color: White
Melting point (°C): 178
Specific rotation [a]20/D: 143 deg (C=4, H2O)

Supplier: Abgent

Polyclonal Antibody Reactivity: Human, Mouse, Isotype: Rabbit Ig, Gene ID: 28955, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 56-82 amino acids from the C-terminal region of human DEXI

Supplier: Abgent

Polyclonal antibody, Isotype: Rabbit Ig, Species Reactivity: Human, Gene ID: 18708, Target/Specificity: Generated from rabbits immunized with a KLH conjugated synthetic peptide between 56-84 amino acids from the N-terminal region of mouse Pik3r1.

Supplier: Abgent

Polyclonal antibody, Isotype: Rabbit Ig, Species Reactivity: Human, Gene ID: 8676, Target/Specificity: Generated from rabbits immunized with a KLH conjugated synthetic peptide between 29-56 amino acids from the N-terminal region of human STX11.

Supplier: Abgent

Polyclonal antibody, Isotype: Rabbit Ig species reactivity: human , Gene ID: 51052, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 27-56 amino acids from the Central region of human PRLH.

Supplier: Abgent

Polyclonal Antibody, Isotype: Rabbit Ig, Species Reactivity: Human, Gene ID: 9144, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 28-56 amino acids from the N-terminal region of human SYNGR2

Supplier: Abgent

Polyclonal Antibody, Host: , Isotype: Rabbit Ig, Species Reactivity: Human, Gene ID: 26257, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 30-56 amino acids from the N-terminal region of human NKX2-8.

Supplier: Abgent

Polyclonal Antibody Reactivity: Human, Isotype: Rabbit Ig, Gene ID: 2653, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 27-56 amino acids from the N-terminal region of human GCSH

Supplier: MilliporeSigma

Cas Number 56-84-8, For Synthesis

Supplier: Abgent

Polyclonal antibody, Isotype: Rabbit Ig, Species Reactivity: Human , Gene ID: 3597, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 56-85 amino acids from the N-terminal region of human IL13RA1

Supplier: Abgent

Polyclonal antibody, Isotype: Rabbit Ig, Species Reactivity: Human, Gene ID: 2182, Target/Specificity: Generated from rabbits immunized with a KLH conjugated synthetic peptide between 28-56 amino acids from the N-terminal region of human ACSL4.

Supplier: Abgent

Polyclonal Antibody, Isotype: Rabbit Ig, Species Reactivity: Human, Gene ID: 259215, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 56-84 amino acids from the N-terminal region of human LY6G6F

Supplier: Abgent

Polyclonal Antibody, Host: , Isotype: Rabbit Ig, Species Reactivity: Human, Gene ID: 10368, Target/Specificity: generated from rabbits immunized with a KLH conjugated synthetic peptide between 28-56 amino acids from the N-terminal region of human CACNG3.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: AVANTOR PERFORMANCE MATERIAL LLC

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: Bachem Americas

Sequence: H-Glu-OH

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: Biotium

CBQCA (3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde) reacts specifically with primary amines to form conjugates that can be analyzed by electrophoretic or chromatographic methods. CBQCA also reacts with hydrophilic peptides and amino sugars. The amine derivatized product (7-aza-1-cyano-5,6-benzisoindole) is highly fluorescent that is optimally excited at 450 nm and have emission maximum at 560 nm.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: Proteintech

CLPP is the putative ATP-dependent Clp protease proteolytic subunit and also named as endopeptidase Clp. It belongs to the peptidase S14 family. Clp cleaves peptides in various proteins in a process that requires ATP hydrolysis. It may be responsible for a fairly general and central housekeeping function rather than for the degradation of specific substrates. This protein has a transit peptide of 56 amino acid.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Supplier: Bioss

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.